在停止梅波利祖马布治疗时,ACT得分的作用
Neha Solanki1, Brittany Beck2, Monica Labadia2
1Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
概括
在严重喘中停止服用梅波利祖马布与男性性别和低喘控制测试分数有关. 这些因素增加了患者停止这种重要的治疗的风险.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
- 现实世界的证据 现实世界的证据
背景情况:
- 梅波利祖马布是一种针对严重喘的向治疗.
- 在美国临床实践中,关于停止使用梅波利祖马布的数据有限.
- 了解停药模式对于优化患者护理至关重要.
研究的目的:
- 评估在严重喘患者中停用梅波利祖马布的现实疗效和停用时间.
- 为了确定与停止梅波利祖马布治疗相关的患者特征.
- 为了测试假设,停止治疗梅波利祖马布的患者在基线时患有更严重,不受控制的喘.
主要方法:
- 在克利夫兰诊所 (2016-2022) 开始接受美波利祖马布的严重喘患者的回顾性分析.
- 数据收集包括基线人口统计,病史,喘控制测试 (ACT) 得分,氧化 (FeNO) 分数分泌和螺旋计.
- 患者被跟踪至少18个月,并分为停止 (B组) 或继续 (A组) 组.
主要成果:
- 28名患者 (B组) 暂停了梅波利祖马布治疗,平均为5.8个月.
- 129名患者 (A组) 继续治疗至少一年.
- 较低的ACT分数 (<13) 显著增加了停止治疗的几率 (OR 6.64),男性性别 (OR 3.39).
结论:
- 在现实环境中,高胆固醇细胞计数可能无法预测梅波利祖马布的益处.
- 大约17%的患者在6个月内停止服用梅波利祖马布.
- 男性性别和较低的ACT分数是严重喘中停用梅波利祖马布的关键预测因素.
更多相关视频
08:58Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
43.0K
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
9.9K
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
Antiasthma Drugs: Methylxanthines
236
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
236
Drugs Used in Lower Respiratory Disorders: Overview
450
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
450
Antiasthma Drugs: Leukotriene Modifiers
317
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
317
Myasthenia Gravis: Diagnostic Tests
883
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
883
